Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Ildong Pharmaceutical
Company facts
- Status
- KOSPI 249420 · ISIN KR7249420001
- Founded
- 2016-08-01
- CEO
- 윤웅섭, 이재준(공동 대표이사)
- Headquarters
- 서울특별시 서초구 바우뫼로27길 2
- Industry
- KSIC 212
- Fiscal year end
- 12
- Links
- Filings · DART · Quote · finance.naver.com · Website
- Source
- DART
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 600,758 | 614,941 | 566,934 |
| Operating income | −53,944 | 13,119 | 19,477 |
| Net income | −80,961 | −12,402 | 23,698 |
| Total assets | 611,261 | 589,043 | 573,031 |
| Total liabilities | 436,995 | 429,985 | 333,517 |
| Total equity | 174,266 | 159,058 | 239,514 |
Unit: KRW million · Consolidated statements · Source DART 사업보고서
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
National R&D projects (NTIS)
41
item
11,637,000,000
Cumulative government R&D funding (KRW)
Largest projects
- HIF-1a의 발현을 조절하는 신규 항암후보물질 도출 2012 · 교육과학기술부
- ID1201의 경증 알츠하이머 치매 환자에서 유효성과 안전성 연구 2016 · 보건복지부
- (임상 2상) ID1201의 경증 알츠하이머 치매 환자에서 유효성과 안전성 연구 2017 · 보건복지부
Korean patent filings (KIPRIS)
The applicant name overlaps with other companies, so no total is given. Listed below are recent filings confirmed under this company's name.
Recently published patents
- 닌테다닙 또는 이의 약학적으로 허용가능한 염 및 메타크릴산 공중합체를 포함하는 약학 제제 20260507
- 6-메톡시피리딘-3-일 유도체를 포함하는 위장관 질환의 치료 방법 20250820
- 신규 바이사이클릭 헤테로아릴 화합물 및 이의 용도 20250314
- 6-메톡시피리딘-3-일 유도체의 중간체 제조방법 20250204
- 6-메톡시피리딘-3-일 유도체의 제조방법 20241205
Papers with affiliated authors (OpenAlex)
No records
Companies in the same readouts
- Dong-A ST
- Chugai Pharmaceutical
- Eli Lilly
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Novo Nordisk
- Hanmi Pharmaceutical
Last updated 2026-09-21